# CJC-1295 Ipamorelin Dosage: The Doses Studied, by Species and Route > CJC-1295 Ipamorelin dosage in research context only: the doses, routes, and half-lives studied for each component, with no human protocol. A cited literature summary. Research-context only — the doses and routes the literature records for each separate component, and why no human protocol for the blend exists. ## The gist This page describes CJC-1295 Ipamorelin dosage strictly as it appears in published studies — what researchers gave to which animals or volunteers, at what amount, by what route. It is not a protocol, and it carries no instruction for anyone to follow. Two facts shape everything here. First, the doses on record are for the *single* components, mostly CJC-1295 in early human pharmacology and ipamorelin in rodents; the fixed blend has no validated human dosing study at all. Second, the two halves clear on wildly different schedules — CJC-1295 with DAC over many days, ipamorelin and the no-DAC "Mod GRF" form within hours — so a single "dose" number for the blend would be meaningless. Where a figure appears below, it is reported as "studied at X in [species] by [route]" and nothing more. ## Cjc 1295 ipamorelin dosage: the doses on record The cleanest human numbers for **cjc 1295 ipamorelin dosage** belong to the CJC-1295 component. In Phase 1 pharmacokinetic studies, CJC-1295 with DAC was administered subcutaneously at 30 to 90 µg/kg in healthy adults, producing the multi-day GH and IGF-1 elevation those studies characterized [1][7]. In GHRH-knockout mouse work, CJC-1295 was used at about 2 µg/day. The no-DAC form — Mod GRF (1-29) — has no formal standalone human pharmacokinetic study; it has been modelled in research protocols on the order of 100–200 µg per injection, reflecting its short pulsatile GHRH signal. Ipamorelin's recorded doses are overwhelmingly preclinical: roughly 100 µg/kg three times daily and 0.5 mg/kg/day in bone studies, 0.01–1 mg/kg intravenously in gastrointestinal-motility work, with about 1 µg/kg plateauing the GH response in rodent models. No validated human pharmacokinetic dosing for ipamorelin has been published. None of these figures constitutes a human protocol for the combination. ## Half-lives studied: the mismatch that matters The pharmacokinetic split is the whole story of the stack. CJC-1295 with DAC has a half-life of roughly six to eight days in humans — albumin-bound, with peptide detectable in rat plasma beyond 72 hours [4]. CJC-1295 without DAC (Mod GRF 1-29) runs on the order of minutes to about thirty minutes, like native GRF(1-29), because DPP-IV (dipeptidyl peptidase-IV, a blood enzyme that clips peptides) cleaves it rapidly. Ipamorelin sits under about two hours in rodent plasma, with peak GH response around 40 minutes post-dose and no validated human half-life published. Pairing a multi-day agent with a sub-two-hour one is precisely why the combination's net GH exposure cannot be inferred from either number alone. ## Routes and handling studied The routes recorded across these studies are subcutaneous and intravenous, plus continuous subcutaneous infusion by osmotic minipump in rodent models and intranasal administration in some ipamorelin rodent pharmacokinetic work. On stability, the published handling context is laboratory-standard: lyophilised (freeze-dried) peptide is stable frozen for extended periods, and after reconstitution with bacteriostatic water (sterile water with 0.9% benzyl alcohol as a preservative) the aqueous solution is kept refrigerated at 2–8 °C and degrades over weeks via asparagine deamidation, with degradation products that can be markedly less potent. Agitation and repeated freeze-thaw are avoided. GHRH analogues undergo DPP-IV cleavage in plasma; CJC-1295's amino-acid substitutions and DAC were engineered specifically to resist it. This is descriptive laboratory-handling context, not a preparation instruction. ## Why no human protocol exists for the blend CJC-1295 with DAC reached Phase 2 before its program was discontinued; ipamorelin was investigated but never approved. Critically, there is no peer-reviewed human pharmacology study of the pre-mixed CJC-1295 Ipamorelin combination, so any "protocol" circulating for the blend is extrapolation from single-component data plus general GHRH+GHRP synergy evidence [3][5]. The class-wide safety review that frames these compounds emphasizes that long-term and large-population data are lacking [6]. For those reasons this page stops at *what was studied* and goes no further: it names doses, species, and routes from the literature, and it does not translate any of them into a human regimen. --- A front-page reading of the CJC-1295 and ipamorelin literature — a register of what the studies established, not a clinic, a vendor, or a prescription.